Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment

作者：Moulis Guillaume^*; Bagheri Haleh; Sailler Laurent; Jonville Bera Annie Pierre; Weber Emmanuelle; Guy Claire; Petitpain Nadine; Laroche Marie Laure; Favreliere Sylvie; Bene Johana; Baldin Bernadette; Villeval Federici Laure; Tebacher Alt Martine; Bres Virginie; Veyrac Gwenaelle; Grandvuillemin Aurelie; Mauprivez Cedric; Lapeyre Mestre Maryse; Montastruc Jean Louis

来源：European Journal of Internal Medicine, 2014, 25(8): 777-780.

DOI：10.1016/j.ejim.2014.09.006

• Thrombopoietin receptor agonist
• Romiplostim
• Eltrombopag
• Adverse drug reaction
• Pharmacovigilance
• Disproportionality analysis

Background: Romiplostim and eltrombopag, the two marketed thrombopoietin receptor agonists (TPO-RAs), have distinct binding sites and might have distinct pharmacodynamic mechanisms. The aim of this study was to compare their adverse drug reaction (ADR) patterns. %26lt;br%26gt;Methods: We selected in the French PharmacoVigilance Database all ADRs associated with TPO-RAs from TPO-RA marketing until the 31st of December 2013. Medical charts were reviewed. We conducted disproportionality analyses comparing romiplostim exposure in the reports of a given ADR pattern (thrombosis, neurological, cutaneous, gastrointestinal or hematological) to romiplostim exposure in all other TPO-RA-related ADR reports. Reporting Odds Ratios (RORs) were adjusted for age and gender. We also compared the number of reports of a given ADR pattern per million daily defined doses (DDDs) dispensed in France during the study period. %26lt;br%26gt;Results: We described 45 reports (53 ADRs) with romiplostim and 26 reports (37 ADRs) with eltrombopag. There were 19 venous thromboses. At least one other risk factor was present in 83.3% of the cases. Ten (55.6%) patients had been splenectomized previously. There were eight arterial thromboses. Another risk factor was noticed in all cases. There was no signal for an excess risk of thrombosis with romiplostim versus eltrombopag (ROR: 1.45, 95% CI [0.48-4.45]). There was a signal for a higher risk of gastrointestinal ADRs with eltrombopag (ROR: 30.28, 95% CI [3.23-383.86]) and of hematological ADRs with romiplostim (ROR: 14.36, 95% CI [1.73-119.08]). Dispensing data-adjusted comparisons led to similar results. %26lt;br%26gt;Conclusions: This study suggests different ADR patterns between romiplostim and eltrombopag.

• 出版日期2014-10